XTX Topco Ltd Decreases Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

XTX Topco Ltd decreased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 51.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,217 shares of the medical device company’s stock after selling 5,550 shares during the quarter. XTX Topco Ltd’s holdings in Tandem Diabetes Care were worth $221,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Brooklyn Investment Group purchased a new stake in Tandem Diabetes Care during the 3rd quarter valued at $28,000. Assetmark Inc. bought a new position in shares of Tandem Diabetes Care during the third quarter valued at $29,000. ORG Wealth Partners LLC purchased a new stake in shares of Tandem Diabetes Care during the third quarter valued at $30,000. Waldron Private Wealth LLC bought a new stake in Tandem Diabetes Care in the 3rd quarter worth about $50,000. Finally, Headlands Technologies LLC raised its position in Tandem Diabetes Care by 110.0% in the 2nd quarter. Headlands Technologies LLC now owns 2,060 shares of the medical device company’s stock worth $83,000 after buying an additional 1,079 shares during the last quarter.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of Tandem Diabetes Care stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now directly owns 195,190 shares in the company, valued at approximately $5,855,700. The trade was a 4.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Price Performance

Shares of Tandem Diabetes Care stock opened at $33.27 on Friday. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -17.24 and a beta of 1.32. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The stock’s 50-day simple moving average is $32.36 and its 200-day simple moving average is $39.17. Tandem Diabetes Care, Inc. has a 52 week low of $21.85 and a 52 week high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $243.97 million for the quarter, compared to analysts’ expectations of $224.14 million. During the same period in the previous year, the firm earned ($0.38) EPS. The firm’s revenue was up 31.4% compared to the same quarter last year. As a group, analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TNDM shares. Barclays raised their price target on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a report on Friday, November 8th. The Goldman Sachs Group initiated coverage on shares of Tandem Diabetes Care in a research report on Friday, October 4th. They issued a “neutral” rating and a $46.00 target price for the company. Canaccord Genuity Group lowered their target price on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Citigroup cut their price target on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada started coverage on shares of Tandem Diabetes Care in a research note on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.